Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomised placebo-controlled trial

Lancet

Volumn 354, Issue 9175, 1999, Pages 287-290

  Bernstein, David I ^a   Sack, David A ^b   Rothstein, Edward ^c   Reisinger, Keith ^d   Smith, Vicki E ^a   O'Sullivan, Donna ^e   Spriggs, Dale R ^e   Ward, Richard L ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Pennridge Pediatric Associates   (United States)

^d Primary Physicians Research   (United States)

^e AVANT Immunotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; ROTAVIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN ROTAVIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS INFECTION; VOMITING;

EID: 0033600431     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)12106-2     Document Type: Article

References (15)

1. Bernstein DI, Ward RL. Rotaviruses. In: Feigin RD, Chery JD, eds. Textbook of pediatric infectious diseases. 4th edn, vol 2. Philadelphia: WB Saunders Company, 1997: 1901-22.
2. Tucker A.W., Haaddix A.C., Bresee J.S.et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 279:1998;1371-1376.
3. Glass R.I., Bresee J.S., Parashar U.et al. Rotavirus vaccine at the threshold. Nat Med. 3:1997;1324-1325.
4. Bernstein DI, Glass RI, Rogers G., et al, for the US Rotavirus Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995; 273: 1191-96.
5. Rennels MB, Glass RI, Dennehy PH, et al, for the US Rotavirus Vaccine Efficacy Group. Safety and efficacy of high dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. Pediatrics 1996; 97: 7-13.
6. Joensuu J., Koskenniemi E., Pang X.L., Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 350:1997;1205-1209.
7. Velazquez F.R., Matson D.O., Calva J.J.et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 335:1996;1022-1028.
8. Ward R.L., Bernstein D.I. Protection against rotavirus disease after natural rotavirus infection. J Infect Dis. 169:1994;900-904.
9. Ward R.L. Mechanisms of protection against rotavirus in humans and mice. J Infect Dis. 174(1):1996;51-58.
10. Bernstein D.I., Smith V.E., Sherwood J.R.et al. Safety and immunogenicity of a live, attenuated human rotavirus vaccine 89-12. Vaccine. 16:1998;381-387.
11. Bernstein D.I., Sander D.S., Smith V.E.et al. Protection from rotavirus reinfection: two year prospective study. J Infect Dis. 164:1991;277-283.
12. Knowlton D.R., Spector D.M., Ward R.L. Development of an improved method to measure neutralizing antibody titers to rotavirus. J Virol Meth. 33:1991;127-134.
13. Moulton L.H., Staat M.A., Santosham M., Ward R.L. The protective effectiveness of natural rotavirus infection in an American Indian population. J Infect Dis. 178:1998;1562-1566.
14. Ward R.L., McNeal M.M., Clemens J.D.et al. Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses. J Clin Microbiol. 29:1991;449-456.
15. Joensuu J., Koskenniemi E., Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J. 17:1998;334-340.